FDA Inter-governmental Working Meeting on Drug Compounding, Nov. 1-2, 2022
- Opening remarks by FDA Commissioner Robert M. Califf
- Meeting Summary
- FDA Responses to Action Items Identified in 2022 Inter-governmental Working Meeting on Drug Compounding
FDA and state regulators met for the 11th annual inter-governmental working meeting to discuss efforts to continue to strengthen oversight of drug compounders in a two-day virtual meeting, Nov. 1-2, 2022. Nearly 300 federal and state regulators participated.
This year’s meeting coincided with the 10th anniversary of the 2012 fungal meningitis outbreak associated with contaminated compounded drugs, which led to the passage and implementation of the Compounding Quality Act.
During the two-day meeting, attendees listened to presentations and discussed several current issues in drug compounding including compounding outside the pharmacy such as in mobile med-spas and IV hydration clinics. Presenters covered state legislative updates, FDA policy updates, inspection updates, and adverse event reporting.
The meeting continues to serve as a forum for state and federal regulators to share information to protect the public from poor quality and potentially harmful compounded drugs.
FDA previously holds inter-governmental working meetings on compounding with state officials and their designated representatives annually.